You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlupentixol
Accession NumberDB00875  (APRD00388)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionFlupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States.
Structure
Thumb
Synonyms
Flupenthixol
Flupenthixole
Flupentixol
Flupentixol
Flupentixol
Flupentixolo
Flupentixolum
External Identifiers
  • FX 703
  • LC 44
  • LU 5-110
  • N 7009
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluanxol 0.5mg - Tabtablet0.5 mgoralLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol 3mg - Tabtablet3 mgoralLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot 10%- Liq Im 100mg/mlsolution100 mgintramuscularLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot 2% -liq Im 20mg/mlsolution20 mgintramuscularLundbeck Canada Inc1995-12-31Not applicableCanada
Fluanxol Depot Inj 100mg/mlliquid100 mgintramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Depot Inj 20mg/mlliquid20 mgintramuscularMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1981-12-311996-09-09Canada
Fluanxol Tab 0.5mgtablet0.5 mgoralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Fluanxol Tab 3mgtablet3 mgoralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1986-12-311996-09-09Canada
Flupentixol Decanoate Injection BPsolution100 mgintramuscularSandoz Canada Incorporated2009-08-27Not applicableCanada
Flupentixol Decanoate Injection BPsolution20 mgintramuscularSandoz Canada IncorporatedNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DepixolLundbeck A/S
FluanxolLundbeck A/S
JexitJohnson
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flupentixol decanoate
ThumbNot applicableDBSALT000928
Flupentixol dihydrochloride
ThumbNot applicableDBSALT000929
Categories
UNIIFA0UYH6QUO
CAS number2709-56-0
WeightAverage: 436.533
Monoisotopic: 436.179618801
Chemical FormulaC23H27F3N2OS
InChI KeyInChIKey=DTTVNHWDONBIKE-DVZOWYKESA-N
InChI
InChI=1S/C23H27F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,20,22,29H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-9,9a-dihydro-4aH-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
[H]C(CCN1CCN(CCO)CC1)=C1C2C=C(C=CC2SC2=C1C=CC=C2)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Thiochromane
  • Alkylarylthioether
  • N-alkylpiperazine
  • Benzenoid
  • Thiopyran
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use in the treatment of schizophrenia and depression
PharmacodynamicsFlupenthixol is an anxiolytic, antidepressive agent and a mood stabilizer. It inhibits the central monoamine receptors, particularly the dopamine D1 and D2 receptors. Therefore, it increases the amount of serotonin and noradrenaline that control mood and thinking, and improves mood.
Mechanism of actionFlupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS.
Related Articles
AbsorptionFairly slow and incomplete after oral administration
Volume of distributionNot Available
Protein bindingHighly bound to plasma proteins (>95%)
Metabolism

Mainly hepatic

Route of eliminationNot Available
Half life19 to 39 hours
ClearanceNot Available
ToxicityLD50=300 mk/kg (Oral in mice); LD50=791 mg/kg (Oral in rats); LD50=87 mk/kg (IV in mice); LD50=37 mg/kg (IV in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9825
Blood Brain Barrier+0.9778
Caco-2 permeable-0.5438
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.92
P-glycoprotein inhibitor IIInhibitor0.859
Renal organic cation transporterInhibitor0.5065
CYP450 2C9 substrateNon-substrate0.8084
CYP450 2D6 substrateSubstrate0.804
CYP450 3A4 substrateNon-substrate0.6921
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.5657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.828
CarcinogenicityNon-carcinogens0.8985
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8385 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6624
hERG inhibition (predictor II)Inhibitor0.7962
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral0.5 mg
Tabletoral3 mg
Solutionintramuscular100 mg
Solutionintramuscular20 mg
Liquidintramuscular100 mg
Liquidintramuscular20 mg
Prices
Unit descriptionCostUnit
Fluanxol Depot 100 mg/ml39.79USD ml
Fluanxol Depot 20 mg/ml7.96USD ml
Fluanxol 3 mg Tablet0.59USD tablet
Fluanxol 0.5 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility0.000346 mg/mlNot Available
logP4.51HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.003 mg/mLALOGPS
logP4.12ALOGPS
logP3.54ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.93 m3·mol-1ChemAxon
Polarizability45.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Smith Kline & French Laboratories; British Patent 925,538; May 8, 1963.
Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline & French Laboratories.

General ReferencesNot Available
External Links
ATC CodesN05AF01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Flupentixol.
AcepromazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Flupentixol.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Flupentixol.
adipiplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Flupentixol.
AgomelatineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Flupentixol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flupentixol.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Flupentixol.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Flupentixol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Flupentixol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol.
AmantadineAmantadine may increase the QTc-prolonging activities of Flupentixol.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Flupentixol.
AmiodaroneFlupentixol may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flupentixol.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Flupentixol.
AmobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amperozide.
AmphetamineFlupentixol may decrease the stimulatory activities of Amphetamine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Flupentixol.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Flupentixol.
ApomorphineApomorphine may increase the QTc-prolonging activities of Flupentixol.
ArformoterolArformoterol may increase the QTc-prolonging activities of Flupentixol.
AripiprazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Aripiprazole.
Arsenic trioxideFlupentixol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherFlupentixol may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Articaine.
AsenapineFlupentixol may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Flupentixol.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Flupentixol.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Flupentixol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Flupentixol.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Flupentixol.
AzaperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Azaperone.
AzelastineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flupentixol.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Flupentixol.
BaclofenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Flupentixol.
BenzocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzocaine.
BenzphetamineFlupentixol may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Flupentixol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Flupentixol.
BortezomibBortezomib may increase the QTc-prolonging activities of Flupentixol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Flupentixol.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Flupentixol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
BrimonidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Flupentixol.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Flupentixol.
BrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flupentixol.
BuprenorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Buprenorphine.
BuserelinBuserelin may increase the QTc-prolonging activities of Flupentixol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flupentixol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol.
ButacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flupentixol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Flupentixol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Flupentixol.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Flupentixol.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Flupentixol.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Flupentixol.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Flupentixol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flupentixol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Flupentixol.
CarisoprodolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.
CeritinibCeritinib may increase the QTc-prolonging activities of Flupentixol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Flupentixol.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Flupentixol.
CetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flupentixol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloroprocaine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Flupentixol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorphenamine.
ChlorphentermineFlupentixol may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Flupentixol.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Flupentixol.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Flupentixol.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flupentixol.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Flupentixol.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Flupentixol.
CisaprideCisapride may increase the QTc-prolonging activities of Flupentixol.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Flupentixol.
CitalopramCitalopram may increase the QTc-prolonging activities of Flupentixol.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Flupentixol.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Flupentixol.
ClemastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Flupentixol.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Flupentixol.
clomethiazoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Flupentixol.
ClomipramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Flupentixol.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flupentixol.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Flupentixol.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.
ClozapineClozapine may increase the QTc-prolonging activities of Flupentixol.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Flupentixol.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Flupentixol.
CocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Flupentixol.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flupentixol.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Flupentixol.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Flupentixol.
CyclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flupentixol.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Flupentixol.
CyproheptadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Flupentixol.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Flupentixol.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Flupentixol.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Flupentixol.
DantroleneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Flupentixol.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flupentixol.
DapoxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapoxetine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Flupentixol.
DasatinibDasatinib may increase the QTc-prolonging activities of Flupentixol.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Flupentixol.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Flupentixol.
DegarelixDegarelix may increase the QTc-prolonging activities of Flupentixol.
deramciclaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Flupentixol.
DesloratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Flupentixol.
DetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flupentixol.
DextroamphetamineFlupentixol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Flupentixol.
DextromoramideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flupentixol.
DezocineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Flupentixol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flupentixol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flupentixol.
DifenoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Flupentixol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flupentixol.
DihydrocodeineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flupentixol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Flupentixol.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Flupentixol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Flupentixol.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Flupentixol.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Flupentixol.
DofetilideDofetilide may increase the QTc-prolonging activities of Flupentixol.
DolasetronDolasetron may increase the QTc-prolonging activities of Flupentixol.
DomperidoneFlupentixol may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flupentixol.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Flupentixol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
DoxylamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Flupentixol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
DronedaroneFlupentixol may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Flupentixol.
DroperidolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol.
EcgonineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Flupentixol is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Flupentixol.
EfavirenzThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Flupentixol.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Flupentixol.
EliglustatFlupentixol may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flupentixol.
EntacaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Flupentixol.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Flupentixol.
EribulinEribulin may increase the QTc-prolonging activities of Flupentixol.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Flupentixol.
ErythromycinErythromycin may increase the QTc-prolonging activities of Flupentixol.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Flupentixol.
EscitalopramFlupentixol may increase the QTc-prolonging activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Flupentixol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Flupentixol.
EstroneThe serum concentration of Estrone can be increased when it is combined with Flupentixol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol.
EthanolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Flupentixol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flupentixol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flupentixol.
EthosuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flupentixol.
EtoperidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Flupentixol.
EtorphineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etorphine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Flupentixol.
EzogabineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Flupentixol.
FelbamateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Flupentixol.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Flupentixol.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flupentixol.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Flupentixol.
FingolimodFingolimod may increase the QTc-prolonging activities of Flupentixol.
FlecainideFlecainide may increase the QTc-prolonging activities of Flupentixol.
FlibanserinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Flupentixol.
FludiazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunitrazepam.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol.
FluspirileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Flupentixol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Flupentixol.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Flupentixol.
FosphenytoinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Flupentixol.
GabapentinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flupentixol is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Flupentixol.
GalantamineGalantamine may increase the QTc-prolonging activities of Flupentixol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Flupentixol.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Flupentixol.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Flupentixol.
GlutethimideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Glutethimide.
GoserelinGoserelin may increase the QTc-prolonging activities of Flupentixol.
GranisetronGranisetron may increase the QTc-prolonging activities of Flupentixol.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Flupentixol.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Flupentixol.
GuanfacineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flupentixol.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Flupentixol.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Flupentixol.
HalothaneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Flupentixol.
HydrocodoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Flupentixol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.
Hydroxyamphetamine hydrobromideFlupentixol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
HydroxyzineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Flupentixol.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Flupentixol.
IbutilideIbutilide may increase the QTc-prolonging activities of Flupentixol.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Flupentixol.
IloperidoneFlupentixol may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Flupentixol.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Flupentixol.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Flupentixol.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Flupentixol.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Flupentixol.
IndalpineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Flupentixol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Flupentixol.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Flupentixol.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Flupentixol.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flupentixol.
IsradipineIsradipine may increase the QTc-prolonging activities of Flupentixol.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Flupentixol.
IvabradineIvabradine may increase the QTc-prolonging activities of Flupentixol.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Flupentixol.
KetamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Flupentixol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flupentixol.
KetobemidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Flupentixol.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Flupentixol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Flupentixol.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Flupentixol.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flupentixol.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Flupentixol.
LapatinibLapatinib may increase the QTc-prolonging activities of Flupentixol.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Flupentixol.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Flupentixol.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Flupentixol.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Flupentixol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Flupentixol.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Flupentixol.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flupentixol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Flupentixol.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Flupentixol.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flupentixol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flupentixol.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Flupentixol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Flupentixol.
LisdexamfetamineFlupentixol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Flupentixol.
LithiumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Flupentixol.
LopinavirFlupentixol may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flupentixol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Flupentixol.
LosartanThe serum concentration of Losartan can be increased when it is combined with Flupentixol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flupentixol.
Lu AA21004The risk or severity of adverse effects can be increased when Flupentixol is combined with Lu AA21004.
LumefantrineFlupentixol may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Flupentixol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flupentixol.
MeclizineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Flupentixol.
MelatoninThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Melperone.
MephentermineFlupentixol may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.
MequitazineFlupentixol may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.
MethadoneMethadone may increase the QTc-prolonging activities of Flupentixol.
MethadoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methadyl Acetate.
MethamphetamineFlupentixol may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flupentixol.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Flupentixol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flupentixol.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Flupentixol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Flupentixol.
MetyrosineFlupentixol may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Flupentixol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Flupentixol.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flupentixol.
MifepristoneMifepristone may increase the QTc-prolonging activities of Flupentixol.
MilnacipranThe risk or severity of adverse effects can be increased when Flupentixol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Flupentixol.
MirabegronMirabegron may increase the QTc-prolonging activities of Flupentixol.
MirtazapineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flupentixol.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Flupentixol.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.
MoexiprilMoexipril may increase the QTc-prolonging activities of Flupentixol.
MolindoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Flupentixol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flupentixol.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Flupentixol.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flupentixol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
NabiloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Flupentixol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Flupentixol.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Flupentixol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Flupentixol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Flupentixol.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Flupentixol.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Flupentixol.
NicardipineNicardipine may increase the QTc-prolonging activities of Flupentixol.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Flupentixol.
NilotinibFlupentixol may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Flupentixol.
NitrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Flupentixol.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Flupentixol.
NormethadoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flupentixol.
OctreotideOctreotide may increase the QTc-prolonging activities of Flupentixol.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Flupentixol.
OlanzapineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olanzapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Flupentixol.
OlopatadineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Flupentixol.
OndansetronOndansetron may increase the QTc-prolonging activities of Flupentixol.
OndansetronThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Flupentixol is combined with Opium.
OrphenadrineFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flupentixol.
OsanetantThe risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Flupentixol.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flupentixol.
OxprenololThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.
OxymorphoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone.
OxytocinOxytocin may increase the QTc-prolonging activities of Flupentixol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Flupentixol.
PaliperidoneFlupentixol may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Flupentixol.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Flupentixol.
ParaldehydeFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Flupentixol.
ParoxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Flupentixol.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.
PazopanibPazopanib may increase the QTc-prolonging activities of Flupentixol.
PentamidinePentamidine may increase the QTc-prolonging activities of Flupentixol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flupentixol.
PerampanelThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Flupentixol.
PerospironeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flupentixol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Flupentixol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flupentixol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenoxyethanol.
PhentermineFlupentixol may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Flupentixol.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flupentixol.
PimozideFlupentixol may increase the QTc-prolonging activities of Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Flupentixol.
PizotifenThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Flupentixol.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Flupentixol.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Flupentixol.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Flupentixol.
PramipexoleFlupentixol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Flupentixol.
PrazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Flupentixol.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Flupentixol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flupentixol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flupentixol.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Flupentixol.
PrimidoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Primidone.
ProcainamideFlupentixol may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flupentixol.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Flupentixol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Flupentixol.
PromazinePromazine may increase the QTc-prolonging activities of Flupentixol.
PromazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flupentixol.
PropafenonePropafenone may increase the QTc-prolonging activities of Flupentixol.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flupentixol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Flupentixol.
PropoxycaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Flupentixol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flupentixol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Flupentixol.
PSD502The risk or severity of adverse effects can be increased when Flupentixol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam.
QuetiapineFlupentixol may increase the QTc-prolonging activities of Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Flupentixol.
QuinidineFlupentixol may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Flupentixol.
RamelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Flupentixol.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Flupentixol.
RanolazineRanolazine may increase the QTc-prolonging activities of Flupentixol.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.
RemifentanilThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flupentixol.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Flupentixol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flupentixol.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Flupentixol.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Flupentixol.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Flupentixol.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Flupentixol.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flupentixol.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Flupentixol.
RitonavirRitonavir may increase the QTc-prolonging activities of Flupentixol.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Flupentixol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Flupentixol.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Flupentixol.
RomifidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Romifidine.
RopiniroleFlupentixol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol.
RotigotineFlupentixol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flupentixol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Flupentixol is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Flupentixol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Flupentixol.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Flupentixol.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Flupentixol.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Flupentixol.
ScopolamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Flupentixol.
SertindoleThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Flupentixol.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Flupentixol.
Sodium oxybateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Flupentixol.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Flupentixol.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Flupentixol.
SorafenibSorafenib may increase the QTc-prolonging activities of Flupentixol.
SotalolSotalol may increase the QTc-prolonging activities of Flupentixol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Flupentixol.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Flupentixol.
StiripentolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Flupentixol.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Flupentixol.
SulpirideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Flupentixol.
SunitinibSunitinib may increase the QTc-prolonging activities of Flupentixol.
SuvorexantThe risk or severity of adverse effects can be increased when Flupentixol is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Flupentixol.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Flupentixol.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Flupentixol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Flupentixol.
TasimelteonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Flupentixol.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Flupentixol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Flupentixol.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Flupentixol.
TelavancinTelavancin may increase the QTc-prolonging activities of Flupentixol.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Flupentixol.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Flupentixol.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Flupentixol.
TetrabenazineFlupentixol may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrodotoxin.
ThalidomideFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flupentixol.
ThiamylalThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flupentixol.
ThioridazineThioridazine may increase the QTc-prolonging activities of Flupentixol.
ThiothixeneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Flupentixol.
TiletamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Flupentixol.
TizanidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Flupentixol.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Flupentixol.
TopiramateThe risk or severity of adverse effects can be increased when Flupentixol is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Flupentixol.
ToremifeneToremifene may increase the QTc-prolonging activities of Flupentixol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flupentixol.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Flupentixol.
TrazodoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Flupentixol.
TriazolamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flupentixol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flupentixol.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Flupentixol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flupentixol.
TriprolidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Flupentixol.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Flupentixol.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Flupentixol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flupentixol.
VandetanibFlupentixol may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Flupentixol.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Flupentixol.
VemurafenibFlupentixol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Flupentixol.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Flupentixol.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Flupentixol.
VigabatrinThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Flupentixol.
VilazodoneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Flupentixol.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Flupentixol.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Flupentixol.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Flupentixol.
VorinostatVorinostat may increase the QTc-prolonging activities of Flupentixol.
VortioxetineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Flupentixol.
ZimelidineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Flupentixol.
ZolazepamThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Flupentixol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flupentixol.
ZonisamideThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zotepine.
ZuclopenthixolFlupentixol may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Ogren SO, Hall H, Kohler C, Magnusson O, Lindbom LO, Angeby K, Florvall L: Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459-74. [PubMed:6149133 ]
  4. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62. [PubMed:7498321 ]
  5. Huettl P, Gerhardt GA, Browning MD, Masserano JM: Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells. J Pharmacol Exp Ther. 1991 May;257(2):567-74. [PubMed:1674528 ]
  6. Nilsson CL, Ekman A, Hellstrand M, Eriksson E: Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology. 1996 Jul;15(1):53-61. [PubMed:8797192 ]
  7. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
  4. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H: Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17. [PubMed:17111172 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Pyridoxal phosphate binding
Specific Function:
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name:
DDC
Uniprot ID:
P20711
Molecular Weight:
53925.815 Da
References
  1. Zhu MY, Juorio AV, Paterson IA, Boulton AA: Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol. 1994 May;112(1):23-30. [PubMed:7913379 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615 ]
  2. Dey S, Hafkemeyer P, Pastan I, Gottesman MM: A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry. 1999 May 18;38(20):6630-9. [PubMed:10350482 ]
  3. Hafkemeyer P, Licht T, Pastan I, Gottesman MM: Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther. 2000 Mar 1;11(4):555-65. [PubMed:10724034 ]
  4. Yang JM, Vassil A, Hait WN: Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol. 2002 Mar 1;63(5):959-66. [PubMed:11911848 ]
  5. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990 Mar 15;50(6):1748-56. [PubMed:1968358 ]
  6. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res. 1991 Jan 1;51(1):67-72. [PubMed:1988108 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23